Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Company Overview

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.75 to $3.93
• 52-Week Range: N/A
• Volume: 63,385 shs
• Average Volume: 82,980 shs
• Market Capitalization: $45.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALRN Stock Analysis - Frequently Asked Questions

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.20.

When did Aileron Therapeutics' stock split?

Shares of Aileron Therapeutics reverse split before market open on Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Aileron Therapeutics IPO?

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 9/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALRN
• CIK: 1420565
• Web: www.aileronrx.com
• Phone: (617) 995-0900
• Fax: N/A
• Employees: 9
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($3.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -74.08%
• Return on Assets: -27.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,670,000
• Free Float: 20,561,000
• Market Cap: $45.72 million
• Optionable: Not Optionable
• Beta: 2.24